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Background: • Cystic Fibrosis(CF) results in recurrent pulmonary infections and CF-related diabetes has been shown to hasten the decline in lung function but screening for diabetes using an Oral Glucose Tolerance Test (OGTT) does not begin until 10 years of age.
• Continuous Glucose Monitoring (CGM) detects hyperglycaemia in CF patients, before the OGTT and is associated with poorer lung function and an increase in respiratory infections with CF pathogens ) was inserted on the back or lower abdomen, during general anaesthetic at the time of BAL and worn for up to 3 days.
• Each child had finger-prick glucose checks (Abbott freestyle optimum Neo TM ) performed 2-3 times per day whilst wearing the device for calibration.
• Routine bronchoscopy is performed on an annual basis and BAL fluid was cultured and used to determine total cell count & neutrophil percentage.
Results:
Conclusion(s): • Very young children with Cystic Fibrosis may demonstrate significant glucose abnormalities on CGM that may be a marker of more severe disease.
• There is a significant correlation between neutrophils on routine bronchoalvolar lavage microscopy and AUC glucose >7.8mmol/L, a novel finding that may indicate an important relationship between early hyperglycaemia and pulmonary inflammation.
• Further research in larger cohort is underway to evaluate the relationship between neutrophilic inflammation and hyperglycemia in children with CF <5years of age. Methods: The PERCH case-control study enrolled 4232 cases of hospitalized WHO-defined severe and very severe pneumonia from nine sites in seven countries (Bangladesh; The Gambia; Kenya; Mali; South Africa; Thailand; and Zambia). At admission each case underwent a standardized assessment of clinical signs and pneumonia risk factors by trained health personnel, and a CXR was taken which was interpreted using the standardized WHO methodology. CXRs were categorized as abnormal (consolidation and/or other infiltrate), normal, or uninterpretable.
Results: CXRs were interpretable in 3587 (85%) cases, of which 1935 (54%) were abnormal (site range 35% to 64%). Cases with abnormal CXRs were more likely than those with normal CXRs to have hypoxemia (45% vs. 26%), crackles (69% vs. 62%), tachypnea (85% vs. 80%), or fever (20% vs. 16%), and less likely to have wheeze (30% vs 38%; all p<0.05). CXRconsolidation was associated with a higher case fatality ratio at 30-day follow up (13.5%) compared to other infiltrate (4.7%) or normal (4.9%) CXRs.
Conclusions: Clinically diagnosed pneumonia cases with abnormal CXRs were more likely to have signs typically associated with pneumonia, but CXR-normal cases were common and clinical signs considered indicative of pneumonia were present in substantial proportions of these cases. CXR-consolidation cases represent a high-risk group. Variations in CXR findings between sites likely reflect major predictors such as etiology, severity, duration of infection, access to care, and environmental conditions. Background: Normal TF is necessary for optimal growth. GH therapy may case changes in the hypothalamic-pituitary-thyroid by centrally inhibit TSH production as well as peripherally increasing T4 to T3 conversion which increases negative feedback on TSH production. PWS is characterized by hypothalamic dysfunction; therefore patients may be at risk of developing central hypothyroidism with GH therapy. We evaluated whether GH therapy in children with PWS presented an increased risk of central hypothyroidism.
QUEENSLAND CHANGES TO THYROID FUNCTION (TF) FOLLOWING GROWTH HORMONE (GH) THERAPY IN CHILDREN WITH PRADER-WILLI SYNDROME (PWS)
Method: We performed a retrospective review of children with PWS. FT4 (Free Thyroxine) and TSH (Thyroid Stimulating Hormone) was assessed before and after GH therapy. Between 2003 and 2014, 60 patients had at least one recorded FT4 and TSH test. FT4 and TSH results were standardized by expressing them as a % of the reference range (RR). x%=100×((x-L)/(U-L)), where x is the test result and U and L are the upper and lower values of the RR. Mean test % were compared to an expected mean of 50% for tests taken one year pre-GH and post-GT. We also assessed change in test % for those who had tests before and after GH commencement (Δ%) using a paired t-test.
Results: In the year prior to GH, most FT4 and TSH were in the low normal range while 4 patients had FT4 below the RR (Table 1) . Following GH therapy, FT4 and TSH decreased further. This effect was sustained for 3 years (Table 2) .
Conclusion: FT4 was significantly lower than expected in patients with PWS. This further decreased during GH therapy. Whether these changes have adverse clinical effects on growth is 
